Analyst Reco. Johnson & Johnson Deutsche Boerse AG

Equities

JNJ0

CA47817E1034

Delayed Deutsche Boerse AG Other stock markets 02:10:06 2024-06-21 am EDT			5-day change	1st Jan Change
13.1 ^EUR	+1.55%		+1.55%	-4.38%

02:19pm	Johnson & Johnson: acquisition of Proteologix completed	CF
02:17pm	Johnson & Johnson Completes Acquisition of Proteologix	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Citigroup Adjusts Price Target on Johnson & Johnson to $180 From $185, Keeps Buy Rating	Jun. 06	MT
Guggenheim Adjusts Johnson & Johnson's Price Target to $160 From $167	May. 01	MT
Redburn Atlantic Adjusts Johnson & Johnson Price Target to $160 From $170	Apr. 25	MT
Daiwa Securities Adjusts Johnson & Johnson's Price Target to $160 From $170, Maintains Outperform Rating	Apr. 22	MT
HSBC Upgrades Johnson & Johnson to Buy From Hold, Raises Price Target to $170 From $169	Apr. 18	MT
DZ Bank Adjusts Johnson & Johnson's Price Target to $176 From $181, Maintains Buy Rating	Apr. 18	MT
Bernstein Adjusts Johnson & Johnson's Price Target to $161 From $172, Maintains Market Perform Rating	Apr. 18	MT
BofA Securities Adjusts Price Target on Johnson & Johnson to $170 From $180, Maintains Neutral Rating	Apr. 17	MT
Morgan Stanley Adjusts Johnson & Johnson's Price Target to $167 From $168, Keeps Equalweight Rating	Apr. 17	MT
RBC Adjusts Johnson & Johnson's Price Target to $175 From $181, Keeps Outperform Rating	Apr. 17	MT
Raymond James Adjusts Johnson & Johnson's Price Target to $170 From $175, Maintains Outperform Rating	Apr. 17	MT
Stifel Cuts Johnson & Johnson's Price Target to $155 From $160	Apr. 16	MT
Morgan Stanley Trims Price Target on Johnson & Johnson to $168 From $169, Keeps Equalweight Rating	Apr. 09	MT
Johnson & Johnson Recommends Shareholders to Reject TRC Capital Investment's Mini-Tender Offer	Apr. 05	MT
J&J recommends shareholders to reject 'mini-tender' offer by TRC Capital Investment	Apr. 04	RE
Guggenheim Trims Price Target on Johnson & Johnson to $167 From $169, Maintains Neutral Rating	Jan. 24	MT
Morgan Stanley Adjusts Price Target on Johnson & Johnson to $169 From $170, Maintains Equalweight Rating	Jan. 24	MT
B. Riley Downgrades Ambrx Biopharma to Neutral From Buy on Heels of Announced Sale to Johnson & Johnson, Adjusts PT to $28 From $26	Jan. 09	MT
Raymond James Raises Johnson & Johnson's Price Target to $175 From $172, Maintains Outperform Rating	Jan. 03	MT
ANALYST RECOMMENDATIONS : Adobe, Airbnb, Netflix, Nike, Etsy...	Dec. 14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST